Lupp, Amelie; apl. Prof. Dr. med.                93 25 678                                  

Kliewer, Andrea;  PD Dr. rer. nat.habil.       93 25 671

Miess-Tanneberg, Elke; Dr. rer. nat             93 25 667

Reinscheid, Rainer; Dr. rer. nat.                  93 25 656

Fritzwanker, Sebastian; Dr. rer. nat.           93 25 661

Blum, Nina Kathleen; Dipl.                         93 25 665    

Kruck, Stephanie                                         93 25 661 

Schiemenz, Ulrike                                       93 25 683

Würl, Swetlana                                            93 25 683

Brendel, Monique                                       93 25 665    

Bechmann, Stefan;  Tierhaus                     93 25 705

• DFG: Auswirkungen einer forcierten Desensitisierung von µ-Opioid-Rezeptoren auf analgetische und atemdepressive      Toleranzentwicklung in vivo
• DFG: Genetische Dissoziation der G-Protein- und Arrestin-gekoppelten Signalübertragung am µ-Opioid-Rezeptor in vivo.
• DFG: Regulierte Endozytose und postendozytotischer Transport von Somatostatin-Rezeptoren
• DFG: Regulation der Opioidtoleranz durch agonist-selektive Phosphorylierung endogener µ-Opioid-Rezeptoren in vivo
• Deutsche Krebshilfe: Somatostatin-Rezeptoren als pharmakologische Zielstrukturen für die Diagnose und Therapie
• SFB TP C05: Echtzeit-Analyse der Phosphorylierung und Dephosphorylierung des μ-Opioid-Rezeptors

1. Sommerfeld  O, Medyukhina A,  Neugebauer S,  Ghait M,  Ulferts S, Lupp A, König R, Wetzker R,  Schulz S, Figge MT,  Bauer M, Press  AT: Targeting Complement C5a Receptor 1 for the Treatment of Immunosuppression in Sepsis. Mol Ther. 2021 Jan 6;29(1):338-346
2. Dasgupta P, Günther T, Reinscheid RK, Zaveri NT, Schulz S: Rapid assessment of G protein signaling of four opioid receptors using a real-time fluorescence-based membrane potential assay. Eur J Pharmacol. 2021 Jan 5;890:173640
3. Werner C, Dirsch O, Dahmen U, Grimm MO, Schulz S, Lupp A. Evaluation of Somatostatin and CXCR4 Receptor Expression in a Large Set of Prostate Cancer Samples Using Tissue Microarrays and Well-Characterized Monoclonal Antibodies. Transl Oncol. 13:100801, 2020
4. Gillis A, Gondin AB, Kliewer A, Sanchez J, Lim HD, Alamein C, Manandhar P, Santiago M, Fritzwanker S, Schmiedel F, Katte TA, Reekie T, Grimsey NL, Kassiou M, Kellam B, Krasel C, Halls ML, Connor M, Lane JR, Schulz S, Christie MJ, Canals M. Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists. Sci Signal. 13:eaaz3140, 2020
5. Kliewer A., Gillis A., Hill R., Schmidl F., Baily C., Kelly E., Henderson G., J., Christie MACdonald, Schulz S.: Morphine-induced respiratory depression is independent of ß-arrestin2 signalling. Br J Pharmacol. 177:2923-2931, 2020
6. Rudeck J, Vogl S, Heinl C, Steinfathz M, Fritzwanker S, Kliewer A, Schulz S, Schönfelder G, Bert B: Analgesic treatment with buprenorphine should be adapted to the mouse strain. Pharmacol Biochem Behav. 191:172877, 2020
7. Kajtazi Y, Kaemmerer D, Sänger J, Schulz S, Lupp A: Somatostatin and chemokine CXCR4 receptor expression in pancreatic adenocarcinoma relative to pancreatic neuroendocrine tumours. J Cancer Res Clin Oncol. 145(10): 2481-2493, 2019
8. Nakai A, Fujimoto J, Miyata H, Stumm R, Narazaki M, Schulz S, Baba Y, Kumanogoh A, Suzuki K: The COMMD3/8 complex determines GRK6 specificity for chemoattractant receptors. J Exp Med. 2019 May 14. pii: jem.20181494
9. Mann A, Moulédous L, Froment C, O'Neill PR, Dasgupta P, Günther T, Brunori G, Kieffer BL, Toll L, Bruchas MR, Zaveri NT, Schulz S: Agonist-selective NOP receptor phosphorylation correlates in vitro and in vivo and reveals differential post-activation signaling by chemically diverse agonists. Sci Signal. 2019; 26;12(574)
10. Mai R, Kaemmerer D, Träger T, Neubauer E, Sänger J, Baum RP, Schulz S, Lupp A: Different somatostatin and CXCR4 chemokine receptor expression in gastroenteropancreatic neuroendocrine neoplasms depending on their origin. Sci Rep. 2019, 9(1):4339
11. Saaber F, Schütz D, Miess E, Abe P, Desikan S, Ashok Kumar, P, Balk S, Huang K, Beaulieu JM, Schulz S, Stumm R: ACKR3 Regulation of neuronal migration requires ACKR3 phosphorylation, but not β-Arrestin.  Cell Rep. 2019, 26(6):1473-1488
12. Kliewer A, Schmiedel F, Sianati S, Bailey A, Bateman JT, Levitt ES, Williams JT, Christie MJ, Schulz  S: Phosphorylation-deficient G-protein-biased μ-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects. Nat Commun. 2019, 10(1):367.       

13. Günther T, Tulipano G, Dournaud P, Bousquet C, Csaba Z, Kreienkamp HJ, Lupp A, Korbonits M, Castaño JP, Wester HJ, Culler M, Melmed S, Schulz S: International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature. Pharmacol Rev. 2018 Oct;70(4):763-835

14. Miess E, Gondin AB, Yousuf A, Steinborn R, Mösslein N, Yang Y, Göldner M, Ruland JG, Bünemann M, Krasel C, Christie MJ, Halls ML, Schulz S, Canals M: Multisite phosphorylation is required for sustained interaction with GRKs and arrestins during rapid μ-opioid receptor desensitization.  Sci Signal. 2018 Jul 17;11(539)

15. Günther T, Dasgupta P, Mann A, Miess E, Kliewer A, Fritzwanker S, Steinborn R, Schulz S: Targeting multiple opioid receptors - improved analgesics with reduced side effects?  Br J Pharmacol. 2018 Jul;175(14):2857-2868

16. Kaemmerer D, Sänger J, Arsenic R, D'Haese JG, Neumann J, Schmitt-Graeff A,. Wirtz RM, Schulz S, Lupp A: Evaluation of somatostatin, CXCR4 chemokine and endothelin A receptor expression in a large set of paragangliomas.  Oncotarget, (8); 89958-89969, 2017
17. Liu X, Si W, Garau C, Jüngling K, Pape HC, Schulz S, Reinscheid RK: Neuropeptide S precursor knockout mice display memory and arousal deficits. Eur J Neurosci. 46(1), 1689-1700, 2017
18. Kliewer A, Reinscheid RK, Schulz S: Emerging Paradigms of G Protein-Coupled Receptor Dephosphorylation. Trends Pharmacol Sci. Jul 38; (7), 621-636, 2017